These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30949837)

  • 1. Biomarkers of Parkinson's disease: 20 years later.
    Yilmaz R; Hopfner F; van Eimeren T; Berg D
    J Neural Transm (Vienna); 2019 Jul; 126(7):803-813. PubMed ID: 30949837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Concept of Prodromal Parkinson's Disease.
    Mahlknecht P; Seppi K; Poewe W
    J Parkinsons Dis; 2015; 5(4):681-97. PubMed ID: 26485429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in Parkinson's disease: Advances and strategies.
    Delenclos M; Jones DR; McLean PJ; Uitti RJ
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(Suppl 1):S106-10. PubMed ID: 26439946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of Parkinson's Disease: An Introduction.
    Titova N; Qamar MA; Chaudhuri KR
    Int Rev Neurobiol; 2017; 132():183-196. PubMed ID: 28554407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upgraded Methodology for the Development of Early Diagnosis of Parkinson's Disease Based on Searching Blood Markers in Patients and Experimental Models.
    Kim A; Nigmatullina R; Zalyalova Z; Soshnikova N; Krasnov A; Vorobyeva N; Georgieva S; Kudrin V; Narkevich V; Ugrumov M
    Mol Neurobiol; 2019 May; 56(5):3437-3450. PubMed ID: 30128652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice.
    Tönges L; Buhmann C; Klebe S; Klucken J; Kwon EH; Müller T; Pedrosa DJ; Schröter N; Riederer P; Lingor P
    J Neural Transm (Vienna); 2022 Sep; 129(9):1201-1217. PubMed ID: 35428925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NINDS Parkinson's disease biomarkers program.
    Rosenthal LS; Drake D; Alcalay RN; Babcock D; Bowman FD; Chen-Plotkin A; Dawson TM; Dewey RB; German DC; Huang X; Landin B; McAuliffe M; Petyuk VA; Scherzer CR; Hillaire-Clarke CS; Sieber BA; Sutherland M; Tarn C; West A; Vaillancourt D; Zhang J; Gwinn K;
    Mov Disord; 2016 Jun; 31(6):915-23. PubMed ID: 26442452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New markers in Parkinson's disease.
    Bougea A
    Adv Clin Chem; 2020; 96():137-178. PubMed ID: 32362317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
    Marek K; Jennings D; Tamagnan G; Seibyl J
    Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers of Parkinson's disease: current status and future perspectives.
    Wang J; Hoekstra JG; Zuo C; Cook TJ; Zhang J
    Drug Discov Today; 2013 Feb; 18(3-4):155-62. PubMed ID: 22982303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can detection and prediction models for Alzheimer's Disease be applied to Prodromal Parkinson's Disease using explainable artificial intelligence? A brief report on Digital Neuro Signatures.
    Tarnanas I; Vlamos P; Harms DR;
    Open Res Eur; 2021; 1():146. PubMed ID: 37645162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-Synuclein as a Biomarker for Parkinson's Disease.
    Atik A; Stewart T; Zhang J
    Brain Pathol; 2016 May; 26(3):410-8. PubMed ID: 26940058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid.
    Kalia LV
    Parkinsonism Relat Disord; 2019 Feb; 59():21-25. PubMed ID: 30466800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From Prodromal to Overt Parkinson's Disease: Towards a New Definition in the Year 2040.
    Berg D; Postuma RB
    J Parkinsons Dis; 2018; 8(s1):S19-S23. PubMed ID: 30584153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers of cognitive decline in Parkinson's disease.
    Lin CH; Wu RM
    Parkinsonism Relat Disord; 2015 May; 21(5):431-43. PubMed ID: 25737398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in the diagnosis of Parkinson's disease.
    Tolosa E; Garrido A; Scholz SW; Poewe W
    Lancet Neurol; 2021 May; 20(5):385-397. PubMed ID: 33894193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers in Parkinson's disease: an update.
    Shtilbans A; Henchcliffe C
    Curr Opin Neurol; 2012 Aug; 25(4):460-5. PubMed ID: 22772875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posturo-locomotor markers of preclinical Parkinson's disease.
    Chastan N; Decker LM
    Neurophysiol Clin; 2019 Apr; 49(2):173-180. PubMed ID: 30686671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease--Report of the JPND Working Group BioLoC-PD.
    Lerche S; Liepelt-Scarfone I; Alves G; Barone P; Behnke S; Ben-Shlomo Y; Berendse H; Burn D; Dodel R; Grosset D; Heinzel S; Hu M; Kasten M; Krüger R; Maetzler W; Moccia M; Mollenhauer B; Oertel W; Roeben B; Sünkel U; Walter U; Wirdefeldt K; Berg D
    Neuroepidemiology; 2015; 45(4):282-97. PubMed ID: 26523894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.